Suppr超能文献

新型1,3,4-三芳基吡唑衍生物的合成、体外抗增殖和抗炎活性以及激酶抑制作用

Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives.

作者信息

El-Gamal Mohammed I, Abdel-Maksoud Mohammed S, Gamal El-Din Mahmoud M, Shin Ji-Sun, Lee Kyung-Tae, Yoo Kyung Ho, Oh Chang-Hyun

机构信息

Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea. Korea, Republic of.

出版信息

Anticancer Agents Med Chem. 2017;17(1):75-84.

Abstract

BACKGROUND

Pyrazole derivatives have been reported as both anticancer and antiinflammatory agents.

OBJECTIVE

This study was conducted to develop new pyrazole derivatives as potential anticancer and/or antiinflammatory agents. Their molecular mechanisms of action have been investigated.

METHOD

a series of new triarylpyrazole derivatives were synthesized. Their in vitro anticancer activity was tested against NCI-58 cancer cell line panel of nine cancer types. The most active compound 1a was tested against sixteen kinases, many of them are known to be over-expressed in leukemia and breast cancer. The most sensitive kinases were V600E-B-RAF, C-RAF, FLT3, and P38α/MAPK14. Compound 1a was further tested for caspase-3/7 activity and LDH release assay as measures of its apoptotic and necrotic activities against RPMI-8226. Moreover, the ability of compounds 1a, 1b, and 1g to inhibit nitric oxide and prostaglandin Eproduction in LPS-induced RAW 264.7 macrophages was also examined.

RESULTS

Compounds 1a, 1c, and 1g showed the highest activities against the cancer cell line panel, with more inhibitory effects against leukemia and breast cancer subpanels. The highest activity was exerted by compound 1a. Its IC50 values against RPMI-8226, K-562 leukemia cell lines, and MDA-MB-468 breast cancer cell line were 1.71 μM, 3.42 μM, and 6.70 μM, respectively. The IC50 of compound 1a against P38α/MAPK14 kinase was 0.515 μM. The caspase activity was increased by 72% and 170% at 1.23 μM and 3.70 μM concentrations of compound 1a, respectively. Furthermore, compound 1b inhibited 80.26% and 95.31% of NO and PGE2 productions, respectively, at 50 μM concentration in the LPS-induced RAW 264.7 macrophages.

CONCLUSION

Compound 1a could kill the cells through induction of apoptosis rather than necrosis. Compound 1a was more selective against cancer cells than non-cancerous cells. In addition, the hydroxyl analogue 1b was the most active as antiinflammatory agent.

摘要

背景

吡唑衍生物已被报道具有抗癌和抗炎作用。

目的

本研究旨在开发新型吡唑衍生物作为潜在的抗癌和/或抗炎药物,并对其作用的分子机制进行研究。

方法

合成了一系列新型三芳基吡唑衍生物,检测了它们对九种癌症类型的NCI-58癌细胞系的体外抗癌活性。对活性最高的化合物1a检测了16种激酶,其中许多激酶在白血病和乳腺癌中过表达。最敏感的激酶是V600E-B-RAF、C-RAF、FLT3和P38α/MAPK14。进一步检测了化合物1a对RPMI-8226细胞的半胱天冬酶-3/7活性和乳酸脱氢酶释放试验,以衡量其凋亡和坏死活性。此外,还检测了化合物1a、1b和1g对脂多糖诱导的RAW 264.7巨噬细胞中一氧化氮和前列腺素E产生的抑制能力。

结果

化合物1a、1c和1g对癌细胞系显示出最高活性,对白血病和乳腺癌亚组的抑制作用更强。化合物1a活性最高。其对RPMI-8226、K-562白血病细胞系和MDA-MB-468乳腺癌细胞系的IC50值分别为1.71 μM、3.42 μM和6.70 μM。化合物1a对P38α/MAPK14激酶的IC50为0.515 μM。在化合物1a浓度为1.23 μM和3.70 μM时,半胱天冬酶活性分别增加了72%和170%。此外,在脂多糖诱导的RAW 264.7巨噬细胞中,化合物1b在50 μM浓度时分别抑制了80.26%和95.31%的一氧化氮和前列腺素E的产生。

结论

化合物1a可通过诱导凋亡而非坏死来杀死细胞。化合物1a对癌细胞的选择性高于非癌细胞。此外,羟基类似物1b作为抗炎剂活性最高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验